ライフサイエンスコーパス: MTCT

1 MTCT risk increased with maternal HBeAg positivity (odds

2 MTCT risk was elevated among women with incident infecti

3 MTCT was related to maternal HBeAg positivity and effect

4 ternal Ab responses may further reduce HIV-1 MTCT.

5 HTLV-1 MTCT was associated with mother's age at delivery of >25

6 an inform targeted measures to reduce HTLV-1 MTCT.

7 ntial of cesarean delivery to prevent HTLV-1 MTCT.

8 amplified env from plasma RNA for 19 HIV-1C MTCT pairs, 10 transmitting in utero (IU) and 9 transmit

9 HIV) through breast-feeding in a study of 59 MTCT cases and 116 controls nested within a cohort of an

10 effect of breast milk erythropoietin against MTCT.

11 ses to provide protection of infants against MTCT from birth through the breastfeeding period and cou

12 ral responses that partially protect against MTCT of HIV is required to inform the development of a m

13 r immediate and prolonged protection against MTCT.IMPORTANCE Our study is the first to evaluate the i

14 h weight (OR: 1.76; 95% CI: 1.07, 2.90), and MTCT of HIV by the time of birth (OR: 2.26; 95% CI: 1.18

15 death, low birth weight, preterm birth, and MTCT of HIV.

16 ncy/postpartum status and HIV incidence, and MTCT risk and rates.

17 incidence of adverse pregnancy outcomes and MTCT of HIV.

18 creased risks of adverse infant outcomes and MTCT of HIV.

19 endpoints were the safety of LdT/LAM use and MTCT rates.

20 We matched 59 incident breastfeeding MTCT cases to 59 nontransmitting controls based on the c

21 he risk of low efavirenz concentrations, but MTCT was rare.

22 In African cohorts, MTCT risk was significantly higher among women with inci

23 highly viremic mothers can further decrease MTCT of HBV.

24 be prioritized, and is critical to decrease MTCT.

25 an alternative strategy that would decrease MTCT of HBV.

26 Clinical trials to determine MTCT among breast-feeding women receiving HAART are need

27 Early MTCT was 2.2% (95% CI: 1.3-3.6) and late MTCT rate was 5

28 Early MTCT was defined as an infant with confirmed HIV infecti

29 receipt of nevirapine did not predict early MTCT in the BF group (P=.45).

30 /mL) was significantly associated with early MTCT (aOR: 6.8, 95% CI: 2.3-19.9).

31 d, they might not be sufficient to eliminate MTCT due to breastfeeding.

32 evalence and incidence settings to eliminate MTCT from breastfeeding.

33 tenatal care to support efforts to eliminate MTCT of HIV and syphilis.

34 program has made large strides to eliminate MTCT.

35 Furthermore, children who escape MTCT are again at risk of infection when they become sex

36 regimens, with 2009 (56%) uptake, estimated MTCT risk would be 14.4% (Option A) or 13.4% (Option B).

37 logistic regression was performed to explore MTCT risk in relation to infant-mother characteristics a

38 method and analyzed the quasispecies of four MTCT pairs that broke through immunoprophylaxis.

39 to estimate the bottleneck effect during HBV MTCT, which provides information to optimize treatment f

40 in The Gambia, we estimated the rate of HBV MTCT and the peripartum care cascade among pregnant wome

41 The primary end point was the rate of HBV MTCT defined by the proportion of HBsAg-positive babies.

42 In The Gambia, the residual risk of HBV MTCT exceeds the elimination absolute target.

43 zation identified major research gaps on HBV MTCT in Africa.

44 n intense intervention package to reduce HBV MTCT in China.

45 ood collection for further retrospective HBV MTCT risk assessment including HBV DNA viral load and HB

46 IMPORTANCE Most HIV-1 and HCMV MTCT occurs in infancy, and the cotransmission of these

47 dy the molecular mechanism of HIV-1 and HCMV MTCT via oral epithelium, we established polarized infan

48 um may serve as an initial mechanism for HIV MTCT.

49 potentially protect against breast milk HIV MTCT.

50 ies for mother-to-child transmission of HIV (MTCT).

51 and HIV-1 loads in breast milk could improve MTCT prevention strategies.

52 r understanding of the genetic bottleneck in MTCT by revealing that viruses transmitted to infants ha

53 d <400 copies/mL, there was no difference in MTCT rate (0% without intravenous ZDV vs 0.6% with intra

54 hould be an important secondary end point in MTCT trials.

55 sion through the oral mucosa and its role in MTCT are poorly understood.

56 ARV treatment in MTCT potentially provides opportunities to better define

57 Maternal TB is associated with increased MTCT of HIV.

58 decanoic acid were associated with increased MTCT, whereas trans FAs were related to higher CAV and C

59 Intrapartum MTCT was associated with placental microtransfusions.

60 y (ART) reduces intrauterine and intrapartum MTCT, whereas maternal post-partum HIV acquisition, untr

61 the decrease in intrauterine and intrapartum MTCT.

62 y in an infant macaque model for intrapartum MTCT.

63 , comparison of env sequences from NT and IU MTCT participants indicated statistically significant di

64 n addition, viral sequences isolated from IU MTCT placental tissue showed variation in env V1 loop le

65 of the eight NT cases and six of the nine IU MTCT cases.

66 ng in utero mother-to-child transmission (IU MTCT), transmitted viral variants must pass through mult

67 opathy differences in Env associated with IU MTCT alter viral cellular tropism or affinity, allowing

68 rly MTCT was 2.2% (95% CI: 1.3-3.6) and late MTCT rate was 5.2 per 1000 person-years (95% CI: 2.5-10.

69 time during the study after enrollment (late MTCT) and associated factors.

70 547 infants in the BF group at risk for late MTCT, 24 (4.4%) were infected.

71 001) and breast milk (P<.001) predicted late MTCT.

72 isit) was significantly associated with late MTCT (IRR: 6.2, 95% CI: 1.2-31.7).

73 ional PMTCT Program led to a projected 12-mo MTCT risk of 20.3%.

74 k (95% confidence interval [CI], 2%-120%) of MTCT of HIV at 6 weeks, a 2-fold higher risk of MTCT of

75 lk exposure to HIV accounts for up to 44% of MTCT.

76 lk exposure to HIV accounts for up to 44% of MTCT.

77 There was 1 case of MTCT.

78 Although the absolute number of cases of MTCT acquired through breastfeeding is decreasing, the r

79 ng is increasing relative to other causes of MTCT.

80 tion of viral quasispecies in the context of MTCT.

81 ssed Uganda's progress toward elimination of MTCT and factors associated with MTCT.

82 opment of new options for the elimination of MTCT as well as policy changes that may help the current

83 Unique features of MTCT and paediatric HIV disease could be helpful in unde

84 mize treatment for reducing the frequency of MTCT.

85 The rapidly increasing incidence of MTCT worldwide has resulted in an urgent need for preven

86 eview, we discuss the proposed mechanisms of MTCT, evidence for cell-free and cell-associated transmi

87 There was an increased odds of MTCT for every log2 increase in maternal sCD14 concentra

88 In all four pairs of MTCT samples, we consistently observed a significant ove

89 We investigated uptake of prevention of MTCT (PMTCT) services, infant feeding recommendations, a

90 viral therapy (HAART) used for prevention of MTCT (PMTCT).

91 V nAbs are associated with the prevention of MTCT of HCV.

92 BV epidemic will need improved prevention of MTCT.

93 6 were HBsAg positive, giving a 2.8% rate of MTCT (95% CI, 1.1%-6.2%).

94 re was no apparent difference in the rate of MTCT among women with subtype A versus D (adjusted odds

95 Outcomes of interest were reduction of MTCT and adverse outcomes to mothers and newborns.

96 e outcomes of interest were the reduction of MTCT and safety in the TDF-treated, TAF-treated, and con

97 maternal plasma predicted a reduced risk of MTCT and mediated autologous virus neutralization, sugge

98 T of HIV at 6 weeks, a 2-fold higher risk of MTCT of HIV through breast-feeding among children who we

99 The risk of MTCT of HIV-1 was comparable with these regimens.

100 tivation may adversely influence the risk of MTCT of HIV.

101 maternal ART adherence increase the risk of MTCT through breastfeeding.

102 s of maternal HIV disease stage, the risk of MTCT was inversely related to 11c,14c-eicosadienoic acid

103 The risk of MTCT was inversely related to breast milk erythropoietin

104 to parasitic antigens increases the risk of MTCT, cord blood mononuclear cells (CBMCs) from Kenyan a

105 FAs in breast milk might reduce the risk of MTCT.

106 envelope was predictive of a reduced risk of MTCT.

107 through 12 months after delivery on risk of MTCT.

108 priming to malaria may increase the risk of MTCT.

109 HBsAg positivity suggests a crucial role of MTCT in maintaining high HBV endemicity in some areas in

110 sociated transmission in different routes of MTCT, and the impact of ARVs on virus levels and transmi

111 al/neonatal vitamin A supplementation has on MTCT, HIV-free survival, and mortality in HIV-exposed in

112 However, development of efficient TCFT or MTCT systems in non-Brassica species had limited success

113 The study found that the overall MTCT rate was 0.23% (39 of 16,908; 95% confidence interv

114 th viral load >/=1000 copies/mL, the overall MTCT rate was higher without than with intravenous ZDV (

115 significant progress in reducing peripartum MTCT of HIV with ART, continued access to ART throughout

116 For infants with maternal HBeAg positivity, MTCT risk was associated with mothers born in the immuni

117 lementation significantly affected postnatal MTCT or overall mortality between baseline and 24 months

118 have suggested that prevention of postnatal MTCT may require both Env-specific IgA and functional Ig

119 rlines an urgent need to effectively prevent MTCT in sub-Saharan Africa.

120 ded, alternative means are needed to prevent MTCT of HIV.

121 ssment of prophylactic programmes to prevent MTCT, including child mortality and infection averted.

122 Thus, immunologic strategies to prevent MTCT, such as an HIV vaccine, will be required to attain

123 ogen design for maternal vaccines to prevent MTCT.IMPORTANCE Efforts to curb HIV-1 transmission in pe

124 While previous MTCT research has investigated the neutralizing antibody

125 t tonsil epithelial tight junctions promotes MTCT of these viruses through tonsil mucosal epithelium,

126 ine versus single-dose nevirapine, to reduce MTCT of HIV among breast-fed infants.

127 Antiviral therapy reduced MTCT, as defined by infant hepatitis B surface antigen s

128 therapy improves HBV suppression and reduces MTCT in women with chronic HBV infection with high viral

129 sible and effective in dramatically reducing MTCT.

130 equal efficacy of the 2 regimens in reducing MTCT (risk ratio: 1.09, 95% CI .15-7.65).

131 tive and without safety concerns in reducing MTCT in highly viremic mothers.

132 ic mothers was equally effective in reducing MTCT.

133 and TDF revealed similar effects on reducing MTCT (risk ratio: 1.09, 95% confidence interval .16-7.61

134 ines the relationship between HIV-1 subtype, MTCT, and the development of Nvp resistance (Nvp(R)) in

135 Our findings suggest that MTCT risk is associated with neutralizing maternal IgG t

136 The MTCT rate was lower among participants who were complian

137 t target of the host immune response, in the MTCT bottleneck.

138 treatment are challenges for preventing the MTCT.

139 859 at-risk infants who underwent PVST, the MTCT rates differed between infants born to HBsAg-positi

140 ared to the control, TDF therapy reduced the MTCT rate in infants aged 6-12 months (risk ratio: 0.10,

141 MV or HIV-1 infection alone, promoting their MTCT at its initial stages via infant oropharyngeal and

142 CMV infection may substantially reduce their MTCT.

143 ) and minimal tissue culture transformation (MTCT) systems have great potential in addressing genotyp

144 ted to prevent Mother-to-child transmission (MTCT) but discontinued at delivery if there is no furthe

145 B virus (HBV) mother-to-child transmission (MTCT) in highly viremic mothers.

146 ng hepatitis B mother-to-child transmission (MTCT) in real-world settings.

147 ven randomised mother-to-child transmission (MTCT) intervention trials, we estimate mortality in Afri

148 B virus (HBV) mother-to-child transmission (MTCT) is a fundamental step toward the HBV elimination g

149 Prevention of mother-to-child transmission (MTCT) is an indispensable component in combatting the gl

150 prophylaxis on mother-to-child transmission (MTCT) is limited using real-world data.

151 e frequency of mother-to-child transmission (MTCT) of HBV in a region, and the risk of chronic HBV in

152 Mother-to-child transmission (MTCT) of HBV remains an important source of incident cas

153 reased risk of mother-to-child transmission (MTCT) of HCV, HCV nAb titers were assessed in 63 mothers

154 Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) is a major route of HBV

155 Perinatal or mother-to-child transmission (MTCT) of hepatitis B virus (HBV) remains the major risk

156 noprophylaxis, mother-to-child transmission (MTCT) of Hepatitis B Virus still occurs in approximately

157 ssociated with mother-to-child transmission (MTCT) of HIV and other adverse pregnancy outcomes.

158 elp to prevent mother-to-child transmission (MTCT) of HIV and syphilis through increased case detecti

159 th the risk of mother-to-child transmission (MTCT) of HIV by breastfeeding and with shedding of cell-

160 The rate of mother-to-child transmission (MTCT) of HIV from breastfeeding is increasing relative t

161 IMPORTANCE As mother to child transmission (MTCT) of HIV plays a major part in the persistence of th

162 Prevention of mother-to-child transmission (MTCT) of HIV remains a major objective where antenatal c

163 th the risk of mother-to-child transmission (MTCT) of HIV, we nested a case-control study (49 pairs o

164 Mother-to-child transmission (MTCT) of HIV-1 has been associated with symptomatic and

165 e mechanism of mother-to-child transmission (MTCT) of HIV-1 is not well described.

166 Mother-to-child transmission (MTCT) of HIV-1 is the major mode of paediatric infection

167 erefore reduce mother-to-child transmission (MTCT) of HIV-1 via breast-feeding.

168 tes of risk of mother-to-child transmission (MTCT) of HIV-1, including responses associated with prot

169 prevention of mother-to-child transmission (MTCT) of HIV-1.

170 prevention of mother-to-child transmission (MTCT) of HIV-1.

171 ssociated with mother-to-child transmission (MTCT) of HIV; the role of maternal tuberculosis (TB), ho

172 egimens reduce mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) but result i

173 Mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) continues to

174 prevention of mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) in high-reso

175 nd the risk of mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) through brea

176 sk factors for mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) via breast-f

177 ing peripartum mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) with antiret

178 ancy outcomes, mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV), and child m

179 isk factor for mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV).

180 Mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1) and

181 for preventing mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1).

182 Mother-to-child transmission (MTCT) of human T-lymphotropic virus type 1 (HTLV-1) is a

183 quired through mother-to-child transmission (MTCT) or failed chemoprophylaxis populates viral reservo

184 testing, and a mother-to-child transmission (MTCT) rate at 12 months of 4.9%; we simulated guideline-

185 outcomes, and mother-to-child transmission (MTCT) risk.

186 route is rare, mother-to-child transmission (MTCT) through the neonatal/infant oral and/or gastrointe

187 f new cases of mother-to-child transmission (MTCT), and yet there are limited data on HIV-1C transmis

188 lly reduce HIV mother-to-child transmission (MTCT), but inconsistent drug access and adherence, as we

189 prevention of mother-to-child transmission (MTCT).

190 into risks of mother to child transmission (MTCT).

191 ostnatal HIV-1 mother-to-child transmission (MTCT).

192 minants of HIV mother-to-child transmission (MTCT).

193 Mother-to-child-transmission (MTCT) of human immunodeficiency virus (HIV) remains a si

194 ed low risk of mother-to-child-transmission (MTCT) was dependent on the C-terminal flank of the V3 cr

195 to compare mother-to-child HIV transmission (MTCT) risk among women with incident versus chronic infe

196 ric HIV: a mother-to-child HIV transmission (MTCT) risk of less than 5%.

197 s among placental microtransfusion, in-utero MTCT, maternal immunosuppression, and poor birth outcome

198 o eradication of incident HBV infections via MTCT include underutilization of immunoprophylaxis with

199 The primary model outcome was MTCT risk at weaning.

200 ow-income and middle-income countries, where MTCT is common, because of difficulty obtaining and deli

201 ional age, and birth weight) associated with MTCT of HIV.

202 ng duration of >6 months was associated with MTCT.

203 mination of MTCT and factors associated with MTCT.

204 venous ZDV and compared its association with MTCT rate and other infant parameters, according to vari

205 thout confirmatory testing, in settings with MTCT rates similar to that of South Africa, more than 10

206 breastfeeding duration were shortened, would MTCT risks at 95% uptake fall below 5%.